BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37833904)

  • 21. The EEF1A2 gene expression as risk predictor in localized prostate cancer.
    Worst TS; Waldbillig F; Abdelhadi A; Weis CA; Gottschalt M; Steidler A; von Hardenberg J; Michel MS; Erben P
    BMC Urol; 2017 Sep; 17(1):86. PubMed ID: 28923030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes and prognosis of metastatic prostate cancer patients ≤ 60-year-old.
    Kim H; Lee S; Byun SS; Hong SK
    World J Urol; 2021 Dec; 39(12):4319-4325. PubMed ID: 34279709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
    Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
    Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of miRNAs in urine of prostate cancer patients.
    Stuopelytė K; Daniūnaitė K; Jankevičius F; Jarmalaitė S
    Medicina (Kaunas); 2016; 52(2):116-24. PubMed ID: 27170485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preoperative serum levels of early prostate cancer antigen (EPCA) predict prostate cancer progression in patients undergoing radical prostatectomy.
    Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
    Prostate; 2012 Feb; 72(3):270-9. PubMed ID: 21630293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
    Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
    Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.
    Suardi N; Gandaglia G; Gallina A; Di Trapani E; Scattoni V; Vizziello D; Cucchiara V; Bertini R; Colombo R; Picchio M; Giovacchini G; Montorsi F; Briganti A
    Eur Urol; 2015 Feb; 67(2):299-309. PubMed ID: 24571959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
    Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
    Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [miR-129 in the diagnosis, treatment and prediction of clinical prognosis of prostate cancer].
    Zhao XD; Tang ZL; Wang ZH; Dong J; Xu S
    Zhonghua Nan Ke Xue; 2022 Nov; 28(11):996-1005. PubMed ID: 37846115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
    Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
    Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
    Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
    Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Local treatment Associated With Prognosis among Men With Metastatic Prostate Cancer: A SEER-Based Study.
    Zhou J; Cao Y; Chen H; Wu Y; Ding J; Qi J
    Clin Genitourin Cancer; 2023 Jun; 21(3):e204-e215. PubMed ID: 36858922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology.
    Kang JJ; Reiter RE; Steinberg ML; King CR
    Eur Urol Oncol; 2018 Oct; 1(5):378-385. PubMed ID: 31158076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
    Schmidt L; Fredsøe J; Kristensen H; Strand SH; Rasmussen A; Høyer S; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
    Ann Oncol; 2018 Sep; 29(9):2003-2009. PubMed ID: 30010760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
    Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
    Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis.
    Cao J; Zhu X; Zhao X; Li XF; Xu R
    PLoS One; 2016; 11(7):e0158770. PubMed ID: 27368058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer.
    Akamatsu S; Kubota M; Uozumi R; Narita S; Takahashi M; Mitsuzuka K; Hatakeyama S; Sakurai T; Kawamura S; Ishidoya S; Hoshi S; Ishida M; Mizuno K; Ogura K; Goto T; Terada N; Kobayashi T; Yamasaki T; Inoue T; Tsuchiya N; Ohyama C; Arai Y; Habuchi T; Morita S; Ogawa O
    Eur Urol Oncol; 2019 May; 2(3):320-328. PubMed ID: 31200847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
    Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
    Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Random forest-based modelling to detect biomarkers for prostate cancer progression.
    Toth R; Schiffmann H; Hube-Magg C; Büscheck F; Höflmayer D; Weidemann S; Lebok P; Fraune C; Minner S; Schlomm T; Sauter G; Plass C; Assenov Y; Simon R; Meiners J; Gerhäuser C
    Clin Epigenetics; 2019 Oct; 11(1):148. PubMed ID: 31640781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.